Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Randomized, Open-Label, Single-Dose Study Assessing the Pharmacokinetics, Safety and Tolerability of Tenofovir Alafenamide, Tenofovir, and Emtricitabine Following Administration of Coformulated Emtricitabine/Tenofovir Alafenamide in Healthy Japanese Subjects

Trial Profile

A Phase I, Randomized, Open-Label, Single-Dose Study Assessing the Pharmacokinetics, Safety and Tolerability of Tenofovir Alafenamide, Tenofovir, and Emtricitabine Following Administration of Coformulated Emtricitabine/Tenofovir Alafenamide in Healthy Japanese Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2018

At a glance

  • Drugs Emtricitabine/tenofovir alafenamide (Primary) ; Cobicistat/darunavir; Darunavir; Ritonavir
  • Indications HIV-1 infections
  • Focus Pharmacokinetics
  • Sponsors Japan Tobacco
  • Most Recent Events

    • 05 Nov 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top